AU759938B2 - Antisense modulation of integrin alpha4 expression - Google Patents

Antisense modulation of integrin alpha4 expression Download PDF

Info

Publication number
AU759938B2
AU759938B2 AU55703/99A AU5570399A AU759938B2 AU 759938 B2 AU759938 B2 AU 759938B2 AU 55703/99 A AU55703/99 A AU 55703/99A AU 5570399 A AU5570399 A AU 5570399A AU 759938 B2 AU759938 B2 AU 759938B2
Authority
AU
Australia
Prior art keywords
antisense
integrin
disease
cells
antisense compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU55703/99A
Other languages
English (en)
Other versions
AU5570399A (en
Inventor
C. Frank Bennett
Thomas P. Condon
Lex M Cowsert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Percheron Therapeutics Ltd
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU5570399A publication Critical patent/AU5570399A/en
Application granted granted Critical
Publication of AU759938B2 publication Critical patent/AU759938B2/en
Assigned to ANTISENSE THERAPEUTICS LTD reassignment ANTISENSE THERAPEUTICS LTD Alteration of Name(s) in Register under S187 Assignors: ISIS PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
AU55703/99A 1998-10-05 1999-08-19 Antisense modulation of integrin alpha4 expression Ceased AU759938B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/166,203 US5968826A (en) 1998-10-05 1998-10-05 Antisense inhibition of integrin α4 expression
US09/166203 1998-10-05
PCT/US1999/018796 WO2000020635A1 (en) 1998-10-05 1999-08-19 ANTISENSE MODULATION OF INTEGRIN α4 EXPRESSION

Publications (2)

Publication Number Publication Date
AU5570399A AU5570399A (en) 2000-04-26
AU759938B2 true AU759938B2 (en) 2003-05-01

Family

ID=22602243

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55703/99A Ceased AU759938B2 (en) 1998-10-05 1999-08-19 Antisense modulation of integrin alpha4 expression

Country Status (10)

Country Link
US (2) US5968826A (enExample)
EP (1) EP1123414B1 (enExample)
JP (2) JP3834204B2 (enExample)
AT (1) ATE352639T1 (enExample)
AU (1) AU759938B2 (enExample)
CA (1) CA2345209C (enExample)
DE (1) DE69934998T2 (enExample)
DK (1) DK1123414T3 (enExample)
ES (1) ES2279632T3 (enExample)
WO (1) WO2000020635A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515513A (ja) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド 核酸の肺送達のための組成物および方法
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
DE19860642A1 (de) * 1998-12-29 2000-07-06 Deutsches Krebsforsch Antisense-Oligonukleotid zur Hemmung der Expression des Adhäsionsmoleküls very late antigen 4 (VLA-4) in menschlichen Zellen
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
WO2004021978A2 (en) * 2002-08-19 2004-03-18 Pharmacia Corporation Antisense modulation of endothelial specific molecule 1 expression
EP1685236A4 (en) * 2003-09-29 2008-01-23 Univ California METHODS FOR MODIFYING ADHESION, DIFFERENTIATION AND MIGRATION OF HEMATOPOIETIC PROGENITOR CELLS
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
NZ554277A (en) * 2004-10-20 2010-09-30 Antisense Therapeutics Ltd Antisense modulation of integrin alpha 4 expression
CA2609343C (en) * 2005-06-07 2015-03-31 Yale University Methods of treating cancer and other conditions or disease states using lfmau and ldt
WO2009045145A1 (en) * 2007-10-05 2009-04-09 Index Pharmaceuticals Ab Novel compounds for the treatment or alleviation of edema, and methods for their use
US8415314B2 (en) * 2008-06-23 2013-04-09 Antisense Therapeutics Limited Methods for treating multiple sclerosis using antisense oligonucleotides
EP2616081A4 (en) * 2010-09-17 2014-01-01 Antisense Therapeutics Ltd METHOD FOR MOBILIZING STEM AND / OR PROGENITOR CELLS
WO2014193625A1 (en) * 2013-05-30 2014-12-04 R-Pharm Overseas, Inc. Fully human antibodies against human receptor integrin alpha-4
AU2016259971B2 (en) * 2015-05-11 2021-12-09 ProGenis Pty Ltd Multiple sclerosis treatment
ES2938883T3 (es) * 2015-11-05 2023-04-17 Los Angeles Childrens Hospital Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
EP3610880A4 (en) * 2017-03-23 2021-01-06 Napajen Pharma, Inc. CANCER CELL ADHESION ACTIVITY INHIBITOR
WO2023039643A1 (en) * 2021-09-20 2023-03-23 Antisense Therapeutics Ltd Methods and kits therefor
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
CN114887034B (zh) * 2022-07-14 2022-10-28 中山莱博瑞辰生物医药有限公司 LLP2A-Ale在制备用于治疗和/或预防外周血淋巴细胞减少症的药物中的用途
EP4573370A1 (en) * 2022-08-16 2025-06-25 Percheron Therapeutics Ltd Biomarkers and uses thereof in diagnosis and treatment of neurological post acute sequelae of covid 19 (npasc)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOSTER 1996 JNL. OF ALLERGY CLINICAL IMMUNOLOGY 98:S270-71 *

Also Published As

Publication number Publication date
JP4168285B2 (ja) 2008-10-22
DE69934998D1 (de) 2007-03-15
JP2002526555A (ja) 2002-08-20
EP1123414B1 (en) 2007-01-24
EP1123414A1 (en) 2001-08-16
EP1123414A4 (en) 2003-10-01
JP3834204B2 (ja) 2006-10-18
ATE352639T1 (de) 2007-02-15
CA2345209A1 (en) 2000-04-13
DE69934998T2 (de) 2007-12-06
US6258790B1 (en) 2001-07-10
AU5570399A (en) 2000-04-26
CA2345209C (en) 2014-04-22
DK1123414T3 (da) 2007-04-10
WO2000020635A1 (en) 2000-04-13
ES2279632T3 (es) 2007-08-16
JP2006141402A (ja) 2006-06-08
US5968826A (en) 1999-10-19

Similar Documents

Publication Publication Date Title
AU755515C (en) Antisense modulation of BCL-X expression
AU765168B2 (en) Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression
US6136603A (en) Antisense modulation of interleukin-5 signal transduction
US6080580A (en) Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
EP1117672B1 (en) Antisense modulation of survivin expression
CA2345209C (en) Antisense modulation of integrin .alpha.4 expression
WO2000017223A1 (en) ANTISENSE MODULATION OF RhoA EXPRESSION
WO2000061602A1 (en) Antisense oligonucleotide modulation of stat3 expression
WO1999057320A1 (en) Antisense modulation of cd40 expression
EP2199299A2 (en) Antisense modulation of survivin expression
US6653133B1 (en) Antisense modulation of Fas mediated signaling
AU765928B2 (en) Antisense modulation of transforming growth factor-beta expression
US5958771A (en) Antisense modulation of cellular inhibitor of Apoptosis-2 expression
WO2000017400A1 (en) ANTISENSE MODULATION OF cREL EXPRESSION
US6077672A (en) Antisense modulation of TRADD expression
WO2000018786A1 (en) Antisense modulation of rip-1 expression
US6030786A (en) Antisense modulation of RhoC expression
WO2000018785A1 (en) Antisense modulation of cd71 expression

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired